LGT Financial Advisors’s ADMA Biologics ADMA Stock Holding History

LGT Financial Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-704	Closed	-$12.1K	–	307
2024 Q4	$12.1K	Buy	+704	New	+$13.2K	0.03%	406

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

LGT Financial Advisors's ADMA Position: Q1 2025 in Review

LGT Financial Advisors sold out of ADMA Biologics (ADMA) in Q1 2025, closing a stake of 704 shares — an estimated $12.1K sold.

LGT Financial Advisors first reported a position in ADMA in Q4 2024 and held it in 1 quarter. The position peaked at $12.1K in Q4 2024. 347 funds tracked by Wall St. Rank hold ADMA as of Q1 2025.

LGT Financial Advisors reported no remaining ADMA Biologics position as of Q1 2025 after selling out during the quarter.
LGT Financial Advisors sold 704 ADMA Biologics shares in Q1 2025, an estimated $12.1K.
LGT Financial Advisors first reported a position in ADMA Biologics in Q4 2024 and held it in 1 quarter.
LGT Financial Advisors's ADMA Biologics position peaked at $12.1K in Q4 2024.
347 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.